Veracyte CFO sells 3,652 shares under 10b5-1 plan

Veracyte’s CFO reported pre-planned stock sales and tax-related share withholding in early September 2026.

Rhea-AI Filing Summary

VERACYTE, INC. (VCYT) reported that Chief Financial Officer Rebecca Chambers sold common stock and had shares withheld for taxes. On September 4, 2026, she sold 2,477 shares at a weighted-average price of $42.8059 and 1,175 shares at $43.7140 in open-market or private transactions under a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,603 shares were withheld at $44.88 per share to satisfy tax withholding obligations upon vesting of restricted stock units and did not represent a sale.

Insider Trade Summary 10b5-1

Net Seller: 3,652 shares

Net Sell 3 txns

Insider Chambers Rebecca

Role Chief Financial Officer

Sold 3,652 shs ($157K)

Type	Security	Shares	Price	Value
Sale	Common Stock F2, F3	2,477	$42.8059	$106K
Sale	Common Stock F2, F4	1,175	$43.714	$51K
Tax Withholding	Common Stock F1	3,603	$44.88	$162K

Holdings After Transaction: Common Stock — 166,025 shares (Direct)

Footnotes (4)

1. F1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
2. F2. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
3. F3. Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
4. F4. Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Key Figures

Shares sold September 4, 2026 (first transaction): 2,477 shares at $42.8059 per share Shares sold September 4, 2026 (second transaction): 1,175 shares at $43.7140 per share Shares withheld for tax withholding: 3,603 shares at $44.88 per share +4 more

7 metrics

Shares sold September 4, 2026 (first transaction) 2,477 shares at $42.8059 per share Open-market or private sale of Veracyte common stock by the CFO

Shares sold September 4, 2026 (second transaction) 1,175 shares at $43.7140 per share Additional open-market or private sale of Veracyte common stock by the CFO

Shares withheld for tax withholding 3,603 shares at $44.88 per share Withholding on September 2, 2026 to satisfy tax obligations on RSU vesting

Total shares sold 3,652 shares Aggregate of both September 4, 2026 sale transactions reported for the CFO

Rule 10b5-1 plan adoption date August 21, 2025 Date the CFO adopted the trading plan governing the reported sales

First sale price range $42.49–$43.47 Range of individual sale prices underlying the first weighted-average price

Second sale price range $43.51–$44.16 Range of individual sale prices underlying the second weighted-average price

Key Terms

Rule 10b5-1 plan, restricted stock units, weighted average sales price, tax withholding obligations

4 terms

Rule 10b5-1 plan regulatory

"transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"in connection with the vesting of certain restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sales price financial

"Represents weighted average sales price. Sale prices for the transactions range"

tax withholding obligations financial

"withheld to satisfy the Reporting Person's tax withholding obligations"

FAQ

What insider transactions did Veracyte (VCYT) report for its CFO?

Veracyte reported that CFO Rebecca Chambers sold 3,652 shares of common stock in two transactions on September 4, 2026, and had 3,603 shares withheld on September 2, 2026 to cover tax withholding on vested restricted stock units.

At what prices did the Veracyte (VCYT) CFO sell shares on September 4, 2026?

On September 4, 2026, the CFO sold 2,477 shares at a weighted-average price of $42.8059 and 1,175 shares at a weighted-average price of $43.7140. Footnotes state the actual sale prices ranged from $42.49–$43.47 and $43.51–$44.16, respectively.

Were the Veracyte (VCYT) CFO’s September 2026 stock sales under a Rule 10b5-1 plan?

Yes. A footnote states the transactions reported on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025, indicating they were pre-arranged under that plan.

Did the Veracyte (VCYT) CFO’s tax withholding transaction represent a sale?

No. The Form 4 explains that the 3,603 shares on September 2, 2026 were withheld to satisfy tax withholding obligations related to vesting restricted stock units and explicitly states this transaction does not represent a sale.

How many Veracyte (VCYT) shares did the CFO dispose of for tax withholding?

The CFO had 3,603 shares of Veracyte common stock disposed of on September 2, 2026 at $44.88 per share to satisfy tax withholding obligations associated with vesting restricted stock units, according to the Form 4 footnote.

Does the Form 4 show the Veracyte (VCYT) CFO’s remaining share holdings?

No. The non-derivative transaction rows report the transactions, but the fields for total shares following the transactions are blank, so remaining holdings are not stated in this Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 07:54 PM Accepted by SEC EDGAR 09/04/2026 - 07:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chambers Rebecca

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		F(1)		3,603	D	$44.88	169,677	D
Common Stock	09/04/2026		S(2)		2,477	D	$42.8059(3)	167,200	D
Common Stock	09/04/2026		S(2)		1,175	D	$43.714(4)	166,025	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.

2. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

3. Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

4. Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)